The Zhitong Finance App learned that Haixi New Pharmaceutical (02637) rose by more than 14% in early trading. As of press release, it had risen 7.35% to HK$200, with a turnover of HK$14.8511 million.

According to the news, Haixi New Pharmaceutical announced that the US clinical trial application for the treatment of neovascular age-related macular degeneration (NaMD), HX9428, an innovative drug candidate developed independently by the company has been approved by the US Food and Drug Administration (FDA) to officially launch a phase II clinical trial; at the same time, the company has initiated a second phase II clinical trial using positive controls (abaxip) in China, and plans to enroll 60 patients.

According to public information, HX9428 is an innovative drug candidate for oral administration. It aims to break through the current limitations of NaMD treatment mainly relying on vitreous injection, provide a convenient dosage plan, and improve patients' long-term treatment compliance. Phase I and phase II dose extension studies have previously been completed. The company said that the approval of Phase II in the US and the launch of a controlled study in China mark important progress in global clinical development. HX9428 has not been approved for marketing, and safety and efficacy require further verification.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.